Arcturus Therapeutics Share Price (NASDAQ: ARCT)

$17.04

▲

-0.26

(-1.5%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Arcturus Therapeutics Stock chart to analyse performance

Arcturus Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$16.68
Today's High:$17.20
$17.04
2.11%
Downside
Day's Volatility :3.0%
Upside
0.9%
52 Weeks Low:$8.04
52 Weeks High:$25.88
$17.04
52.82%
Downside
52 Weeks Volatility :68.93%
Upside
34.16%

Arcturus Therapeutics Stock Returns

Period	Arcturus Therapeutics Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	32.83%	3.6%	0.0%
6 Months	8.51%	-7.7%	0.0%
1 Year	-12.25%	-12.6%	0.0%
3 Years	10.27%	10.2%	-4.1%

Arcturus Therapeutics Holdings Inc Key Stats

Check Arcturus Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$17.3
Open	$17.195
Today's High	$17.195
Today's Low	$16.68
Market Capitalization	$461.9M
Today's Volume	$523.4K
52 Week High	$25.88
52 Week Low	$8.04
Revenue TTM	$122.1M
EBITDA	$-69.3M
Earnings Per Share (EPS)	$-2.22
Profit Margin	-49.27%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-24.58%

Stock Returns calculator for Arcturus Therapeutics Stock including INR - Dollar returns

The Arcturus Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Arcturus Therapeutics investment value today

Current value as on today

₹93,164

Returns

₹6,836

(-6.84%)

Returns from Arcturus Therapeutics Stock

₹12,120 (-12.12%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Arcturus Therapeutics Stock

-42%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Arcturus Therapeutics Stock from India on INDmoney has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Arcturus Therapeutics Holdings Inc

Name
Holdings %
Name
Holdings %
Federated Hermes Inc
17.29%
BlackRock Inc
10.17%
Nikko Asset Management Americas Inc
7.09%
Sumitomo Mitsui Trust Group Inc
6.75%
Vanguard Group Inc
6.67%
ARK Investment Management LLC
6.32%

Analyst Recommendation on Arcturus Therapeutics Stock

Rating

Trend

Buy

87%Buy

6%Hold

6%Sell

Based on 16 Wall street analysts offering stock ratings for Arcturus Therapeutics(by analysts ranked 0 to 5 stars)

Arcturus Therapeutics Share Price Target

What analysts predicted

Upside of 310.15%

Target:

$69.89

Current:

$17.04

Arcturus Therapeutics share price target is $69.89, a slight Upside of 310.15% compared to current price of $17.04 as per analysts' prediction.

Arcturus Therapeutics Stock Insights

Price Movement
In the last 7 days, ARCT stock has moved down by -8.1%
Decreasing Revenue
Revenue is down for the last 2 quarters, 29.38M → 28.30M (in $), with an average decrease of 3.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -30.00M → -9.18M (in $), with an average increase of 83.3% per quarter
ARCT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 89.3%
ARCT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 94.8%
Price to Sales
ForARCT every $1 of sales, investors are willing to pay $3.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Arcturus Therapeutics Holdings Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$20.8M	↑ 31.97%
Net Income	$-26.0M	↑ 19.31%
Net Profit Margin	-125.02%	↑ 13.27%

	FY20	Y/Y Change
Revenue	$9.5M	↓ 54.12%
Net Income	$-72.1M	↑ 177.59%
Net Profit Margin	-756.35%	↓ 631.33%

	FY21	Y/Y Change
Revenue	$12.4M	↑ 29.56%
Net Income	$-203.7M	↑ 182.3%
Net Profit Margin	-1.6K%	↓ 891.63%

	FY22	Y/Y Change
Revenue	$205.8M	↑ 1564.82%
Net Income	$9.3M	↓ 104.59%
Net Profit Margin	4.54%	↑ 1652.52%

	FY23	Y/Y Change
Revenue	$157.7M	↓ 23.33%
Net Income	$-29.7M	↓ 417.95%
Net Profit Margin	-18.84%	↓ 23.38%

	FY24	Y/Y Change
Revenue	$138.4M	↓ 12.27%
Net Income	$-80.9M	↑ 172.3%
Net Profit Margin	-58.49%	↓ 39.65%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$32.6M	↑ 29.99%
Net Income	$-26.8M	↑ 129.07%
Net Profit Margin	-82.27%	↓ 35.59%

	Q2 FY24	Q/Q Change
Revenue	$46.0M	↑ 41.04%
Net Income	$-17.2M	↓ 35.8%
Net Profit Margin	-37.45%	↑ 44.82%

	Q3 FY24	Q/Q Change
Revenue	$38.8M	↓ 15.58%
Net Income	$-6.9M	↓ 59.9%
Net Profit Margin	-17.78%	↑ 19.67%

	Q4 FY24	Q/Q Change
Revenue	$21.0M	↓ 45.9%
Net Income	$-30.0M	↑ 334.67%
Net Profit Margin	-142.88%	↓ 125.1%

	Q1 FY25	Q/Q Change
Revenue	$29.4M	↑ 39.91%
Net Income	$-14.1M	↓ 53.09%
Net Profit Margin	-47.91%	↑ 94.97%

	Q2 FY25	Q/Q Change
Revenue	$28.3M	↓ 3.68%
Net Income	$-9.2M	↓ 34.78%
Net Profit Margin	-32.44%	↑ 15.47%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-11.7M	↑ 848.01%

	FY20	Y/Y Change
Profit	$-46.4M	↑ 298.31%

	FY21	Y/Y Change
Profit	$-161.4M	↑ 247.79%

	FY22	Y/Y Change
Profit	$58.2M	↓ 136.09%

	FY23	Y/Y Change
Profit	$154.8M	↑ 165.74%

	FY24	Y/Y Change
Profit	$134.8M	↓ 12.89%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Profit	$31.7M	↑ 15.68%

	Q2 FY24	Q/Q Change
Profit	$45.1M	↑ 42.22%

	Q3 FY24	Q/Q Change
Profit	$2.5M	↓ 94.37%

	Q4 FY24	Q/Q Change
Profit	$21.0M	↑ 727.1%

	Q1 FY25	Q/Q Change
Profit	$29.4M	↑ 39.91%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-6.4M	↓ 68.95%
Investing Cash Flow	$-818.0K	↓ 103.7%
Financing Cash Flow	$41.9M	↑ 310.69%

	FY20	Y/Y Change
Operating Cash Flow	$-42.9M	↑ 565.03%
Investing Cash Flow	$-1.7M	↑ 112.96%
Financing Cash Flow	$436.1M	↑ 940.74%

	FY21	Y/Y Change
Operating Cash Flow	$-135.0M	↑ 215.07%
Investing Cash Flow	$-3.4M	↑ 95.52%
Financing Cash Flow	$48.0M	↓ 88.99%

	FY22	Y/Y Change
Operating Cash Flow	$32.0M	↓ 123.69%
Investing Cash Flow	$-7.7M	↑ 126.83%
Financing Cash Flow	$-2.9M	↓ 105.95%

	FY23	Y/Y Change
Operating Cash Flow	$-18.1M	↓ 156.57%
Investing Cash Flow	$-2.9M	↓ 62.45%
Financing Cash Flow	$-24.1M	↑ 742.5%

	FY24	Y/Y Change
Operating Cash Flow	$-59.7M	↑ 230.11%
Investing Cash Flow	$-648.0K	↓ 77.66%
Financing Cash Flow	$5.4M	↓ 122.49%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-5.6M	↑ 920.25%
Investing Cash Flow	$-240.0K	↓ 71.33%
Financing Cash Flow	$2.2M	↓ 112.17%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-30.1M	↑ 442.41%
Investing Cash Flow	$-328.0K	↑ 36.67%
Financing Cash Flow	$2.4M	↑ 9.83%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-23.8M	↓ 21.16%
Investing Cash Flow	$-80.0K	↓ 75.61%
Financing Cash Flow	$693.0K	↓ 71.16%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-284.0K	↓ 98.8%
Investing Cash Flow	$-2.4K	↓ 96.94%
Financing Cash Flow	$134.0K	↓ 80.66%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-35.1M	↑ 12272.54%
Investing Cash Flow	$-137.0K	↑ 5498.69%
Financing Cash Flow	$15.2M	↑ 11239.55%

Arcturus Therapeutics Technicals Summary

Sell

Neutral

Buy

Arcturus Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Arcturus Therapeutics Holdings Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arcturus Therapeutics Holdings Inc	38.33%	8.51%	-12.25%	10.27%	-59.88%
Regeneron Pharmaceuticals, Inc.	3.92%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-15.42%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	11.08%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arcturus Therapeutics Holdings Inc	10.3	NA	NA	-2.36	-0.25	-0.13	NA	8.51
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arcturus Therapeutics Holdings Inc	Buy	$461.9M	-59.88%	10.3	-49.27%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Organization	Arcturus Therapeutics
Employees	174
CEO	Mr. Joseph E. Payne M.Sc.
Industry	Health Technology

Key Management of Arcturus Therapeutics Holdings Inc

Name	Title
Mr. Joseph E. Payne M.Sc.	Founder, President, CEO & Director
Dr. Padmanabh Chivukula Ph.D.	Founder, Chief Scientific Officer, COO & Secretary
Mr. Andrew H. Sassine MBA	CFO & Director
Mr. Lance Kurata	Chief Legal Officer
Ms. Neda Safarzadeh	Vice President and Head of IR/PR & Marketing
Ms. Natasha O. Bowman	Chief Human Resources Officer
Mr. Kevin T. Skol	Chief Business Officer
Dr. Juergen Froehlich FCPh, M.D., MBA	Chief Medical Officer
Dr. Igor Smolenov M.D., Ph.D.	Chief Development Officer
Ms. Roberta Duncan	Chief Strategy Officer

Important FAQs about investing in ARCT Stock from India :

What is Arcturus Therapeutics share price today?

Arcturus Therapeutics share price today is $17.04 as on August 30, 2025 at 1:29 am IST at the close of the market. Arcturus Therapeutics share today touched a day high of $17.20 and a low of $16.68.

What is the 52 week high and 52 week low for Arcturus Therapeutics share?

Arcturus Therapeutics share touched a 52 week high of $25.88 and a 52 week low of $8.04. Arcturus Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $17.04, lower by 34.16% versus the 52 week high.

How to invest in Arcturus Therapeutics Stock (ARCT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Arcturus Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arcturus Therapeutics Shares that will get you 0.0880 shares as per Arcturus Therapeutics share price of $17.04 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Arcturus Therapeutics Stock (ARCT) from India?

Indian investors can start investing in Arcturus Therapeutics (ARCT) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Arcturus Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Arcturus Therapeutics share’s latest price of $17.04 as on August 30, 2025 at 1:29 am IST, you will get 0.5869 shares of Arcturus Therapeutics. Learn more about fractional shares .

What are the returns that Arcturus Therapeutics has given to Indian investors in the last 5 years?

Arcturus Therapeutics stock has given -59.88% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?